Celularity Fulfills Nasdaq Listing Rule, Retires $41.6mln Debt, and Unveils Growth Plans

Celularity has filed its Form 10-Q quarterly reports for Q1 and Q2 2025, regaining Nasdaq Listing Rule 5250(c)(1) compliance. The company has also retired $32 million in senior secured debt and $9.6 million in unpaid interest. Celularity has undergone a strategic restructuring to enhance operational focus and market expansion, with plans to amplify wound care sales, advance three late-stage pipeline products, and explore new market opportunities.

Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, has filed its quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025. The filings, made on August 29, 2025, mark a significant milestone as the company regains compliance with Nasdaq Listing Rule 5250(c)(1) [1].

The company also announced that it has retired $32 million in senior secured debt and $9.6 million in unpaid interest, further strengthening its financial position. Additionally, Celularity has undergone a strategic restructuring, establishing operating subsidiaries for each of its functional business units to enhance operational focus and market expansion [1].

Celularity's Chairman and CEO, Robert J. Hariri, M.D., Ph.D., commented on the developments, stating that the company has "regained compliance with the Nasdaq Listing Rule 5250(c)(1) and retired all senior secured debt and the associated general security interest on Company assets." He added that the company is now well positioned to access traditional working capital facilities, which it intends to use to fuel renewed wound care-related sales growth and advance its three late-stage 510(k) pipeline products, along with capitalizing on new opportunities like stem cell product sales in Florida and elsewhere [1].

The company's quarterly reports provide a comprehensive overview of its financial health and operational performance during the first half of 2025. Despite facing challenges such as a significant secured debt overhang and directional uncertainty around wound care product reimbursement policy, Celularity has demonstrated resilience and a strategic focus on growth opportunities.

Investors should closely monitor Celularity's progress as it navigates the complexities of the biopharmaceutical industry. The company's ability to convert its high-royalty-yield assets into consistent cash flows will be critical in justifying its debt burden and maintaining financial stability [2].

References:
[1] https://www.morningstar.com/news/globe-newswire/9522502/celularity-announces-filing-of-form-10-q-quarterly-reports-for-the-first-quarter-and-the-second-quarter-2025-confirmation-of-nasdaq-listing-rule-5250c1-compliance
[2] https://www.ainvest.com/news/royalty-pharma-2-billion-debt-offering-strategic-fuel-growth-growing-liability-2509/